Skip to main content
Launch offer40% off your first paymentEnds 31 DecemberSee plans
CatalYm logo

CatalYm

Biotech & Pharmaceuticals
WebsiteLinkedIn

CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors.

Open roles
1
Company size
1 - 50 employees
Headquarters
Am Klopferspitz 19, 82152 Planegg-Martinsried

Follow CatalYm

Create an exact-company alert for on-site matches and optional daily email.

Open roles